Loading clinical trials...

Sapphire II PRO US Clinical Study | Clinical Trials | Clareo Health

COMPLETEDNA

Sapphire II PRO US Clinical Study

Sapphire II PRO - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Procedural Success of the Sapphire II PRO 1.0 and 1.25 mm PTCA Dilatation Catheters.

NCT03052530•OrbusNeich

View on ClinicalTrials.gov

Summary

A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters in subjects with stenotic coronary arteries or bypass grafts during percutaneous coronary intervention. Sixty (60) subjects will be treated at up to 5 U.S. sites with the Sapphire II PRO diameters 1.0 and 1.25 mm PTCA dilatation catheters to pre-dilate coronary arteries or bypass grafts during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through hospital discharge.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subject is ≥ 18 years of age.
•2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.
•3. Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.
•4. Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia.
•5. Subject must have de novo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. An embolic protection device must be used in all Saphenous venous grafts (SVG) interventions performed during the index procedure.
•6. A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.
•7. Target and non-target lesions must be located in different coronary arteries or bypass grafts.
•8. Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may include chronic total occlusions (CTO)
•9. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success.

Exclusion Criteria

•1. Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.
•2. Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours prior to index procedure.
•3. Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure.
•4. Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
•5. A serum creatinine level \> 2.0 mg/dl within seven days prior to index procedure.
•6. Cerebrovascular accident (CVA) within the past 6 months.
•7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
•8. Subject has a known left ventricular ejection fraction (LVEF) \<30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary)
•9. More than two lesions requiring treatment.
•10. Unprotected left main coronary artery disease.(Greater than 50% diameter stenosis)
+9 more criteria

Locations (4)

University of Miami

Miami, Florida, United States

Piedmont Heart Institute

Atlanta, Georgia, United States

Peninsula Regional Medical Center

Salisbury, Maryland, United States

The Christ Hospital Heart and Vascular

Cincinnati, Ohio, United States

Key Dates

Start Date

May 5, 2017

Primary Completion Date

July 24, 2017

Completion Date

July 24, 2017

Last Updated

May 11, 2018

Enrollment

ACTUAL participants

Conditions

Coronary Artery DiseaseCoronary DiseaseMyocardial IschemiaHeart DiseasesArteriosclerosisCardiovascular Diseases

Interventions

Sapphire II PRO

DEVICE

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702

Coronary Artery Disease

View study

RECRUITING

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 11, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sapphire II PRO US Clinical Study

Inclusion Criteria

Exclusion Criteria

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

"Erectile Function After PCI in MI and Non-MI Patients"

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

Product Surveillance Registry

Essential Pro Study ( rEPIC04E-HK )

Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)